March 19-21
Bergamo Italy
Visit our booth #2
Conference Information
Join us in Bergamo for the EACR Conference, The Tumor Ecosystem: Cellular Interactions and Therapeutic Opportunities.
Meet our scientists on-site and discover our universal, end-to-end spatial biology solution, answering the needs of the scientific community from early discovery to late-stage translational and clinical research.
Our solutions allow you to minimize validation challenges and move fast from biomarker discovery to translational research.
Want to know more about our spatial biology solutions? Send us a message and secure a meeting with the team.
Join us to hear from world-class experts who are at the forefront of the tumour microenvironment field, sharing their latest discoveries and insights about this cutting-edge research and its implications for novel cancer therapies.
March 20
Industry Spotlight Presentation
March 20
8:45 AM - 9:00 AM
Speaker
Alioune Ndoye, Ph.D.
Technical Sales Representative
Lunaphore Technologies
March 20
Poster Presentation
TB11: Tumor microenvironment: Tumor/stromal interactions
The tumor microenvironment (TME) consists of malignant cells and supporting non-malignant cellular and non-cellular components that form the tumor stroma. The tumor stroma plays an important role in tumor progression and has emerged as a modulator of anti-tumor immunity and responses to therapy. Current protein-based approaches to characterizing and better understanding the cell composition of the tumor stroma face many limitations, such as reagent availability and lengthy protocols. In this study, we identified 22 markers to characterize non-tumoral immune cells, fibroblasts, and endothelial cells in the TME, in a single tissue slide. We propose an approach that overcomes reagent incompatibility and opens new avenues of research on tumor stroma.
Multiorgan Tumor Microarray (TMA) was interrogated with sequential immunofluorescence (seqIF™) panel encompassing protein markers enabling characterization of TME. A 22-plex panel was created based on expanding an already established 13-plex panel (CD3, CD4, CD8, CD11c, CD20, CD45, CD56, CD68, aSMA, FoxP3, Ki67, PD1, PD-L1) by adding 9 additional antibodies (CD11b, CD14, CD31, CD47, CK, FAP, LaminB1, SIRPα, Vimentin). Hyperplex immunofluorescent staining was performed using the automated staining-imaging COMET™ platform. Postprocessing of images was done with HORIZON™ image analysis software.
We established a panel of 22 markers that can be analyzed simultaneously on a single tissue slide despite limited variability in primary antibody species. Using seqIF™ protocol allowed the study of colocalization and co-expression of markers not compatible to study simultaneously in the traditional immunofluorescence approach. Our hyperplex data revealed the distinct composition of the stromal compartment between different tumor types, highlighting high heterogeneity in the tissue composition and stromal architecture.
COMET™ platform enabled studying in detail TME components and highlighted the heterogeneity of tumor stroma across different tissue types. SeqIF™ protocol lifted the limitation imposed by same-species antibodies and allowed simultaneous interrogation of markers’ expression, preserving their spatial relationship.
Speaker
Victoria Wosika, Ph.D.
Scientific Marketing Manager
Lunaphore Technologies